Your browser doesn't support javascript.
loading
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis.
Jingfan, Zhang; Ling, Li; Cong, Liu; Ping, Li; Yu, Chen.
Afiliação
  • Jingfan Z; Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
  • Ling L; Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
  • Cong L; Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
  • Ping L; Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
  • Yu C; Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
Arch Endocrinol Metab ; 63(5): 478-486, 2019.
Article em En | MEDLINE | ID: mdl-31271575
OBJECTIVES: To provide a meta-analysis of the clinical efficacy and safety of sodium glucose co-transporter 2 inhibitors (SGLT2-i), as a combination treatment with metformin in type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control with metformin alone. MATERIALS AND METHODS: We have searched randomized controlled trials (RCTs) in the database: MEDLINE, Embase and Cochrane Collaborative database. We used mean differences (MD) to assess the efficacy of glycemic and other clinical parameters, and risk ratios (RR) to evaluate the adverse events for safety endpoints. The heterogeneity was evaluated by I2. RESULTS: Finally 9 studies were included. SGLT2-i plus metformin had higher reduction level in HbA1C [MD = -0.50, 95% CI (-0.62, -0.38), p < 0.00001], FPG [MD = -1.12, 95%CI (-1.38, -0.87), p < 0.00001], body weight [MD = -1.72, 95% CI (-2.05, -1.39), p < 0.00001], SBP [MD = -4.44, 95% CI (-5.45, -3.43), p < 0.00001] and DBP [MD = -1.74, 95% CI (-2.40, -1.07), p < 0.00001] compared with metformin monotherapy. However, SGLT2-i plus metformin group had higher risk of genital infection [RR = 3.98, 95% CI (2.38, 6.67), p < 0.00001]. No significant difference was found in the risk of hypoglycemia, urinary tract infection or volume related adverse events. CONCLUSIONS: Although the risk of genital infection may increase, SGLT2-i plus metformin may provide an attractive treatment option to those T2DM patients who are unable to achieve glycemic control with metformin alone, based on its effects on glycemic control, reducing body weight and lowering blood pressure.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose / Hipoglicemiantes / Metformina Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Revista: Arch Endocrinol Metab Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose / Hipoglicemiantes / Metformina Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Revista: Arch Endocrinol Metab Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: Brasil